Advanced-therapy access platform
Vialen makes advanced treatments available internationally through qualified provider networks, defined care pathways and one accountable access experience.
Designed around independent clinical decision-making and transparent roles.
Global access pathway
A global platform shaped around people, context, and accountable decisions.
One access layer across fragmented healthcare systems.
We connect the qualified international treatment supply and institutional relationships that make advanced-therapy access easier to understand and coordinate.
Vialen does not provide clinical care, operate facilities. Our role is to organize accountable access pathways.
A connected access environment
Vialen Health
Patients & families
Physicians & health plans
Patient organizations
Institutional partners
Why access is fragmented
Innovation travels faster than access.
Advanced therapies increasingly reach different markets at different times. Provider availability, regulatory approvals, pricing and treatment pathways remain highly local.
01
Availability varies by market
A therapy available today in one country may remain unavailable or impractical in another.
02
Treatment supply is fragmented
Providers, therapies, pricing and eligibility are rarely presented through one comparable access model.
03
Cross-border episodes are undefined
Families often enter complex treatment pathways without clear scope, timelines or expected economics.
The Vialen access model
One access model. Built for complex care.
Vialen aligns the critical access elements in one shared structure—so each participant can better understand their role, information, and next step.
01 — Foundation
Qualified Network
A rigorous, evolving view of treatment supply and partner readiness.
02 — Structure
Defined Care Pathways
A shared structure for the questions, documentation, timing, and coordination each pathway requires.
03 — Experience
One Accountable Experience
One organized interface for the people and institutions participating in access.
The platform structures access coordination. Treating teams retain clinical judgment.
Current access program
CAR-T Therapy Access China
Access commercially approved CAR-T therapies through qualified treatment centers in China, with a defined pathway for international patients and referring physicians.
Multiple Myeloma
B-cell Lymphomas
Selected Solid Tumors
Availability depends on diagnosis, prior treatment, biomarker profile and physician assessment.
Defined access pathway
How access works
From case review to a defined treatment pathway.
Vialen structures each access episode around provider evaluation, treatment scope, expected timelines and cross-border requirements.
01 - ACCESS REVIEW
Establish the relevant pathway
Review the case context and identify the treatment pathways and information required for provider evaluation.
02 - PROVIDER EVALUATION
Obtain qualified clinical review
Relevant treatment centers assess eligibility, availability and the clinical requirements for proceeding.
03 - DEFINED EPISODE
Structure the treatment pathway
Clarify treatment scope, expected timeline, economics and cross-border requirements before travel.
04 - TREATMENT & HANDOFF
Maintain continuity across systems
Keep the access pathway coordinated through treatment and transition back to the patient’s home medical team.
Clinical eligibility and treatment decisions remain with licensed treating providers. Vialen structures the access pathway around those decisions.
ACCESS FOR INDIVIDUALS AND INSTITUTIONS
One access platform. Two ways to engage.
Vialen provides a standardized access model for patients, families, referring professionals and institutional buyers.
For patients & families
Understand your available pathway.
Explore relevant treatment options, qualified provider access, expected timelines and cross-border requirements through one structured entry point.
Request Access
For organizations & referring professionals
Extend access through a defined network.
Connect patients or covered populations to qualified advanced-therapy programs through a standardized provider and access model.
Discuss an Access Program
Governance & clinical independence
Clear roles preserve independent decisions.
Clinical eligibility and treatment decisions remain with licensed treating providers. Vialen structures the access pathway around those decisions, with clear roles, transparent responsibilities and defined handoffs across organizations.
Independent clinical judgment
Clinical decisions remain with licensed treating teams and institutions.
Transparent responsibilities
Roles, obligations and handoffs are defined across the access pathway.
Structured information exchange
Relevant information is organized to support continuity, consent and accountable coordination.